Small bowel carcinoid (enterochromaffin cell) neoplasia exhibits transforming growth factor-β1-mediated regulatory abnormalities including up-regulation of c-Myc and MTA1

Cancer

Volumn 109, Issue 12, 2007, Pages 2420-2431

  Kidd, Mark ^a   Modlin, Irvin M ^a   Pfragner, Roswitha ^b   Eick, Geeta N ^a   Champaneria, Manish C ^a   Chan, Anthony K ^a   Camp, Robert L ^a   Mane, Shrikant M ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

c Myc; Carcinoid; Enterochromaffin cell; Growth inhibition; MTA1; Neoplasia; Neuroendocrine; Transcription; Transforming growth factor (TGF )

Indexed keywords

CELL PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MYC PROTEIN; PROTEIN MTA1; SMAD2 PROTEIN; SMAD4 PROTEIN; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; UVOMORULIN;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER INVASION; CARCINOID; CELL PROLIFERATION; CONTROLLED STUDY; CYTOSTASIS; ENTEROCHROMAFFIN CELL; GLIOBLASTOMA; HUMAN; HUMAN CELL; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; SMALL INTESTINE CANCER; TRANSCRIPTION INITIATION; TUMOR GROWTH;

BLOTTING, WESTERN; CADHERINS; CARCINOID TUMOR; CELL PROLIFERATION; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE INHIBITOR P21; ENTEROCHROMAFFIN CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASES; HUMANS; INTESTINAL NEOPLASMS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-MYC; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA1; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 34250180918     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22725     Document Type: Article

References (67)

1. Modlin I, Lye K, Kidd M. A five-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97:934-959.
2. Champaneria M, Chan A, Kidd M, Eick G, Modlin I. A three-decade analysis of 3,911 small intestinal carcinoids: The rapid pace of no progress. Am J Gastroenterol. 2007 Mar 27; [Epub ahead of print].
3. Modlin IM, Kidd M, Latich I, Zikusoka MN, Shapiro MD. Current status of gastrointestinal carcinoids. Gastroenterology. 2005;128:1717-1751.
4. Tang LH, Luque EA, Efstathiou JA, et al. Gastrin receptor expression and function during rapid transformation of the enterochromaffin-like cells in an African rodent. Regul Pept. 1997;72:9-18.
5. Modlin IM, Lye KD, Kidd M. Carcinoid tumors of the stomach. Surg Oncol. 2003;12:153-172.
6. Kidd M, Eick G, Shapiro MD, Camp RL, Mane SM, Modlin IM. Microsatellite instability and gene mutations in transforming growth factor-beta type II receptor are absent in small bowel carcinoid tumors. Cancer. 2005;103:229-236.
7. Ghimenti C, Lonobile A, Campani D, Bevilacqua G, Caligo M. Microsatellite instability and allelic losses in neuroendocrine tumors of the gastroenteropancreatic system. Int J Oncol. 1999;15:361-366.
8. Zikusoka M, Kidd M, Eick G, Latich I, Modlin I. The molecular genetics of gastroenteropancreatic neuroendocrine tumors. Cancer. 2005;104:2292-2309.
9. Kytola S, Hoog A, Nord B, et al. Comparative genomic hybridization identifies loss of 18q22-qter as an early and specific event in tumorigenesis of midgut carcinoids. Am J Pathol. 2001;158:1803-1808.
10. Hahn SA, Schutte M, Hoque AT, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science. 1996;271:350-353.
11. Massague J, Gomis RR. The logic of TGFbeta signaling. FEBS Lett. 2006;580:2811-2820.
12. Chaudhry A, Oberg K, Gobi A, Heldin C, Funa K. Expression of transforming growth factors beta 1, beta 2, beta 3 in neuroendocrine tumors of the digestive system. Anticancer Res. 1994;14:2085-2091.
13. Massague J, Blain SW, Lo RS. TGFbeta signaling in growth control, cancer, and heritable disorders. Cell. 2000;103:295-309.
14. Akhurst RJ, Derynck R. TGF-beta signaling in cancer - a double-edged sword. Trends Cell Biol. 2001;11:S44-51.
15. Siegel PM, Massague J. Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat. Rev Cancer. 2003; 3:807-821.
16. Katuri V, Tang Y, Marshall BL, et al. Inactivation of ELF/TGF-beta signaling in human gastrointestinal cancer. Oncogene. 2005;24:8012-8024.
17. Jennings M, Pietenpol J. The role of transforming growth factor beta in glioma progression. J Neurooncol. 1998;36:123-140.
18. Seoane J, Le H, Shen L, Anderson S, Massague J. Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Cell. 2004; 117:211-223.
19. Lollgen RM, Hessman O, Szabo E, Westin G, Akerstrom G. Chromosome 18 deletions are common events in classical midgut carcinoid tumors. Int J Cancer. 2001;92:812-815.
20. Guo SS, Wu X, Shimoide AT, Wong I, Sawicki MP. Anomalous overexpression of p27(Kip1) in sporadic pancreatic endocrine tumors. J Surg Res. 2001;96:284-288.
21. Kawahara M, Kammori M, Kanauchi H, et al. Immunohistochemical prognostic indicators of gastrointestinal carcinoid tumours. Eur J Surg Oncol. 2002;28:140-146.
22. Wang D, Johnson C, Buchanan K. Oncogene expression in gastroenteropancreatic neuroendocrine tumors: implications for pathogenesis. Cancer. 1997;80:668-675.
23. Wimmel A, Wiedenmann B, Rosewicz S. Autocrine growth inhibition by transforming growth factor beta-1 (TGFbeta-1) in human neuroendocrine tumour cells. Gut. 2003;52:1308-1316.
24. Myeroff LL, Parsons R, Kim SJ, et al. A transforming growth factor beta receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability. Cancer Res. 1995;55:5545-5547.
25. Parsons R, Myeroff LL, Liu B, et al. Microsatellite instability and mutations of the transforming growth factor beta type II receptor gene in colorectal cancer. Cancer Res. 1995;55: 5548-5550.
26. Markowitz S, Wang J, Myeroff L, et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science. 1995;268:1336-1338.
27. Kidd M, Modlin I, Mane S, Camp R, Eick G, Latich I. The role of genetic markers, NAP1L1, MAGE-D2 and MTA1, in defining small intestinal carcinoid neoplasia. Ann Surg Oncol. 2006;13:253-262.
28. Modlin I, Kidd M, Latich I, et al. Genetic differentiation of appendiceal carcinoid malignancy - a guide for the perplexed. Ann Surg. 2006;244:52-60.
29. Tannapfel A, Vomschloss S, Karhoff D, et al. BRAF gene mutations are rare events in gastroenteropancreatic neuroendocrine tumors. Am J Clin Pathol. 2005;123:256-260.
30. Derynck R, Zhang Y. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature. 2003;425:577-584.
31. Modlin IM, Kidd M, Eick G, Champaneria M. The functional characterization of normal and neoplastic EC cells. J Clin Endocrinol Metab. 2006;91:2340-2348.
32. Pfragner R, Wirnsberger G, Niederle B, et al. Establishment of a continuous cell line from a human carcinoid of the small intestine (KRJ-I): characterization and effects of 5-azacytidine on proliferation. Int J Oncol. 1996;8:513-520.
33. Evers BM, Townsend CM Jr, Upp JR, et al. Establishment and characterization of a human carcinoid in nude mice and effect of various agents on tumor growth. Gastroenterology. 1991;101:303-311.
34. Quinn L, Moore G, Morgan T, Woods L. Cell lines from human colon carcinoma with unusual cell products, double minutes and homogeneously stained regions. Cancer Res. 1979;39:4914-4924.
35. Kolby L, Bernhardt P, Ahlman H, et al. A transplantable human carcinoid as model for somatostatin receptor-mediated and amine transporter-mediated radionuclide uptake. Am J Pathol. 2001;158:745-755.
36. Kidd M, Eick G, Modlin I, Pfragner R, Champaneria M, Murren J. Further delineation of the continuous human neoplastic enterochromaffin (EC) cell line, KRJ-I, and the inhibitory effects of lanreotide and rapamycin. J Mol Endocrinol. 2007;38:181-192.
37. Hayflick L. Subculturing Human Diploid Fibroblast Cultures. New York: Academic Press; 1973.
38. Zatelli MC, Tagliati F, Taylor JE, Rossi R, Culler MD, degli Uberti EC. Somatostatin receptor subtypes 2 and 5 differentially affect proliferation in vitro of the human medullary thyroid carcinoma cell line TT. J Clin Endocrinol Metab. 2001;86:2161-2169.
39. Kidd M, Modlin I, Mane S, Camp R, Shapiro M. Q RT-PCR detection of chromogranin A: a new standard in the identification of neuroendocrine tumor disease. Ann Surg. 2006;243:273-280.
40. Vandesompele J, De Prefer K, Pattyn F, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002;3:RESEARCH0034.
41. Kidd M, Nadler B, Mane S, et al. GeneChip, geNorm and gastrointestinal neoplasia: novel reference genes for real-time PCR. Physiol Genomics. In press.
42. Yakicier M, Irmak M, Romano A, Kew M, Ozturk M. Smad2 and Smad4 gene mutations in hepatocellular carcinoma. Oncogene. 1999;18:4879-4883.
43. Tang LH, Modlin IM, Lawton GP, Kidd M, Chinery R. The role of transforming growth factor alpha in the enterochromaffin-like cell tumor autonomy in an African rodent mastomys. Gastroenterology. 1996;111:1212-1223.
44. Kidd M, Modlin I, Eick G, Camp R, Mane S. The role of CCN2/CTGF in the proliferation of Mastomys enterochromaffin-like cells and gastric carcinoid development. Am J Physiol. 2007;292:G191-200.
45. Wang Z-G, Zhao W, Ramachandra M, Seth P. An oncolytic adenovirus expressing soluble transforming growth factor-b type 11 recepror for Targeting breasr cancer: in vitro evaluation. Mol Cancer Ther. 2006;5:367-373.
46. Tang Y, Katuri D, Dillner A, Mishra B, Deng CX, Mishra L. Disruption of transforming growth factor-beta signaling in ELF-beta-spectrin-deficient mice. Science. 2003;299:574-577.
47. Adhikary S, Eilers M. Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol. 2005; 6:635-645.
48. Oskarsson T, Trumpp A. The Myc trilogy: lord of RNA polymerases. Nat Cell Biol. 2005;7:215-217.
49. Rogulski K, Cohen D, Corcoran D, Benos P, Prochownik E. Deregulation of common genes by c-Myc and its direct target, MT-MC1. Proc Natl Acad Sci U S A. 2005;102:18968-18973.
50. Shi Y, Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell. 2003;113:685-700.
51. Samson WK. Putting the brakes on lactotrope hyperplasia. Trends Endocrinol Metab. 2006;17:2-3.
52. Hendy GN, Kaji H, Sowa H, Lebrun JJ, Canaff L. Menin and TGF-beta superfamily member signaling via the Smad pathway in pituitary, parathyroid and osteoblast. Horm Metab Res. 2005;37:375-379.
53. Wolf N, Krohn K, Bieger S, Frodin M, Gammeltoft S, Krieglstein K, Unsicker K. Transforming growth factor-beta, but not ciliary neurotrophic factor, inhibits DNA synthesis of adrenal medullary cells in vitro. Neuroscience. 1999;90:629-641.
54. Zhang L, Sato E, Amagasaki K, Nakao A, Naganuma H. Participation of an abnormality in the transforming growth factor-beta signaling pathway in resistance of malignant glioma cells to growth inhibition induced by that factor. J Neurosurg. 2006;105:119-128.
55. Sebestyen A, Barna G, Nagy K, et al. Smad signal and TGFbeta induced apoptosis in human lymphoma cells. Cytokine. 2005;30:228-235.
56. Pring M, Prime S, Parkinson EK, Paterson I. Dysregulated TGF-beta1-induced Smad signalling occurs as a result of defects in multiple components of the TGF-beta signalling pathway in human head and neck carcinoma cell lines. Int J Oncol. 2006;28:1279-1285.
57. Halder SK, Beauchamp RD, Datta PK. Smad7 induces tumorigenicity by blocking TGF-beta-induced growth inhibition and apoptosis. Exp Cell Res. 2005;307:231-246.
58. Tvrdik D. The effect of TGFbeta1 on the expression and phosphorylation of key cell-cycle regulators in malignant B cells. Med Sci Monit. 2004;10:BR447-454.
59. Li X, Zhang YY, Wang Q, Fu SB. Association between endogenous gene expression and growth regulation induced by TGF-beta1 in human gastric cancer cells. World J Gastroenterol. 2005;11:61-68.
60. Lebman DA, Edmiston JS, Chung TD, Snyder SR. Heterogeneity in the transforming growth factor beta response of esophageal cancer cells. Int J Oncol. 2002;20:1241-1246.
61. Claassen GF, Hann SR. A role for transcriptional repression of p21CIP1 by c-Myc in overcoming transforming growth factor beta-induced cell-cycle arrest. Proc Natl Acad Sci U S A. 2000;97:9498-9503.
62. Zhang X, DeSalle L, Patel J, et al. Metastasis-associated protein 1 (MTA1) is an essential effector of the c-MYC oncoprotein. Proc Natl Acad Sci U S A. 2005;102:13968-13973.
63. Hofer M, Tapia C, Browne T, Mirlacher M, Sauter G, Rubin M. Comprehensive analysis of the expression of the metastasis-associated gene 1 in human neoplastic tissue. Arch Pathol Lab Med. 2006;130:989-996.
64. Fujimoto K, Sheng H, Shao J, Beauchamp RD. Transforming growth factor-beta1 promotes invasiveness after cellular transformation with activated Ras in intestinal epithelial cells, Exp Cell Res. 2001;266:239-249.
65. Xie W, Bharathy S, Kim D, Haffty BG, Rimm DL, Reiss M. Frequent alterations of Smad signaling in human head and neck squamous cell carcinomas: a tissue microarray analysis. Oncol Res. 2003;14:61-73.
66. Xie W, Mertens JC, Reiss DJ, et al. Alterations of Smad signaling in human breast carcinoma are associated with poor outcome: a tissue microarray study. Cancer Res. 2002;62:497-505.
67. Tannapfel A, Anhalt K, Hausermann P, et al. Identification of novel proteins associated with hepatocellular carcinomas using protein microarrays. J Pathol. 2003;201:238-249.